Session Information

  • WCLC 2021

    2021 World Conference on Lung Cancer

    Conference Program for 2021 the World Conference on Lung Cancer

    Presentation Date(s):  
    • September 8 - 14, 2021
    • Total Presentations: 1107

    All times listed are in Mountain Time MDT (UTC-6:00)

    PL - Plenary
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    FP - Featured Posters
    P - Posters
    WS - Workshops
    IS - Industry Symposium
    MTE - Meet the Expert
    BEDG - Brain Exchange Discussion Groups

Filter Results:

Show Only CME Accredited Sessions

  • +

    MA02 - RET and Novel Combinations of Osimertinib

    • 09:30 - 10:30
    • 9/08/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Mini Oral
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      MA02.01 - Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial

      09:30 - 09:35  |  Presenter: Shun Lu

      • Abstract

      Loading...

  • +

    FP04 - Immunotherapy (Phase II/III Trials)

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters (Featured)
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      FP04.02 - RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC

      00:00 - 00:00  |  Presenter: Jie Wang

      • Abstract

      Loading...

  • +

    P17 - Immunotherapy (Phase II/III Trials) - First-Line, Advanced, Squamous NSCLC

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      P17.02 - RATIONALE 307: A Subgroup Analysis of Tislelizumab Plus Chemo vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC

      00:00 - 00:00  |  Presenter: Shun Lu

      • Abstract

      Loading...

  • +

    P45 - Novel Therapeutics and Targeted Therapies - ALK/ROS1/MET

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P45.06 - Overall Survival From a Phase 2 Study of Crizotinib in East Asian Patients With ROS1+ Advanced Non-Small-Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Yi-Long Wu

      • Abstract

      Loading...

    • +

      P45.08 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China

      00:00 - 00:00  |  Presenter: Shun Lu

      • Abstract

      Loading...

  • +

    P47 - Novel Therapeutics and Targeted Therapies - Clinical Trial in Progress

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      P47.03 - Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer: Stage 2

      00:00 - 00:00  |  Presenter: Jonathan Goldman

      • Abstract

      Loading...

  • +

    P60 - Predictive Tumor Based Assays/ Biomarkers/ Pathology - Other Biomarkers

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
    • +

      P60.12 - Prevalence of c-Met overexpression (c-Met+) and Impact of Prior Lines of Treatment on c-Met Protein Expression in NSCLC

      00:00 - 00:00  |  Presenter: Monica Motwani

      • Abstract

      Loading...

  • +

    P70 - Tumor Biology and Systems Biology: Basic and Translational Science - Omics Analysis of Lung Cancer

    • 00:00 - 00:00
    • 9/08/2021
    • Location: ePoster Hall
    • Not for CME Credit
    • Type: Posters
    • Track: Tumor Biology and Systems Biology: Basic and Translational Science
    • +

      P70.09 - NOTCH1 Mutations in East Asian Patients With Non-Small-Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Qian Wang

      • Abstract

      Loading...

    • +

      P70.11 - Prevalence and Clinicopathological Characteristics of ARID1A Mutations in East Asian Patients With Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Qian Wang

      • Abstract

      Loading...

    • +

      P70.13 - Different Types of ERBB3 Mutations in Chinese Non-Small Cell Lung Cancer Patients

      00:00 - 00:00  |  Presenter: Qian Wang

      • Abstract

      Loading...

    • +

      P70.14 - PRKDC Mutations Recurrently Found in Non-Small Cell Lung Cancer in East Asian Patients

      00:00 - 00:00  |  Presenter: Qian Wang

      • Abstract

      Loading...

    • +

      P70.15 - Mutational Subtypes and Prognosis of East Asian Non-Small-Cell Lung Cancer Harboring NF2 Mutations

      00:00 - 00:00  |  Presenter: Qian Wang

      • Abstract

      Loading...

    • +

      P70.16 - Epidemiological Study of FGFR3 Mutations Among Non-Small Cell Lung Cancer Patients in China

      00:00 - 00:00  |  Presenter: Qian Wang

      • Abstract

      Loading...

    • +

      P70.17 - Molecular Characteristics and Prognosis TERT Mutations in East Asian Non-Small-Cell Lung Cancer Patients

      00:00 - 00:00  |  Presenter: Qian Wang

      • Abstract

      Loading...

    • +

      P70.18 - Distribution of GNAS Mutations in Chinese Patients With Non-Small Cell Lung Cancer

      00:00 - 00:00  |  Presenter: Qian Wang

      • Abstract

      Loading...

    • +

      P70.19 - Clinicopathologic Characteristics of Patients With LRP1B Mutations in Chinese Non-Small Cell Lung Cancer Patients

      00:00 - 00:00  |  Presenter: Qian Wang

      • Abstract

      Loading...

  • +

    OA09 - Expanding Immunotherapy Options for Non-Small Cell Lung Cancers

    • 09:30 - 10:30
    • 9/09/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Immunotherapy (Phase II/III Trials)
    • +

      OA09.01 - First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA

      09:30 - 09:40  |  Presenter: David Carbone

      • Abstract

      Loading...

  • +

    WS06 - Joint IASLC - CAALC - CSCO Workshop: Looking Toward the Future: Recognizing and Curing Lung Cancer

    • 22:15 - 23:45
    • 9/11/2021
    • Location: Program Auditorium
    • Not for CME Credit
    • Type: Workshop
    • Track: N.A.
    • +

      WS06.05 - RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC

      22:53 - 23:03  |  Presenter: Jie Wang

      • Abstract

      Loading...

    • +

      WS06.07 - Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety Data from a Phase 2 Study in China

      23:13 - 23:23  |  Presenter: Shun Lu

      • Abstract

      Loading...

  • +

    OA15 - Upcoming Molecular Targeted Agents for EGFR exon 20 Insertion and MET Skipping Mutation

    • 18:45 - 19:45
    • 9/12/2021
    • Location: Program Auditorium
    • IASLC CME Accredited
    • Type: Oral
    • Track: Novel Therapeutics and Targeted Therapies
    • +

      OA15.04 - Telisotuzumab Vedotin (teliso-v) Monotherapy in Patients With Previously Treated c-Met+ Advanced Non-Small Cell Lung Cancer

      19:15 - 19:25  |  Presenter: D. Ross Camidge

      • Abstract

      Loading...